The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How are clinical trials designed to maximize inclusivity & provide data about a variety of patients?
Ian Thomas
December 19, 2022
During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, Know AML was pleased to speak to Ian Thomas, Cardiff University, Cardiff, UK. We asked, How are acute myeloid leukemia (AML) clinical trials designed to maximize inclusivity and provide data about a wide variety of patients?
Thomas discusses strategies used to formulate clinical trials to allow for accurately reliable data to be gathered. Thomas goes on to explain how using varying genders, age groups, and trial locations are necessary factors in ensuring the data gathered provides an accurate representation of the general population.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
